Treatment Response Prediction for MPN and MDS Patients
Research type
Research Study
Full title
An investigation into the feasibility of an intelligent machine learning based methodology to predict patient response to the standard protocol treatment for Myeloproliferative Neoplasms and Myelodysplastic Syndromes
IRAS ID
224448
Contact name
Michael S Gallimore
Contact email
Sponsor organisation
University of Lincoln
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
In the treatment of Myeloproliferative Neoplasm (MPN) and Myelodysplastic Syndrome (MDS), the individual patient response to the standard treatment protocol is unknown at the outset. In some cases, patients can undergo 6 months of treatment with little response, and thus an alternative treatment regime may have proven more appropriate. This not only affects patient outcomes but also has significant financial implications for the health service. The ability to predict the likely patient response, therefore, at the outset of treatment is significant. This project proposes an initial pilot feasibility study, using data from a small number of patients with known responses, to determine whether it is possible to develop an intelligent mathematical model to make such predictions during the early stages of treatment.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
18/SW/0123
Date of REC Opinion
8 May 2018
REC opinion
Favourable Opinion